Biogened SA

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLBIOGN00018
PLN
21.60
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Biogened SA stock-summary
stock-summary
Biogened SA
Pharmaceuticals & Biotechnology
Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Company’s product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.
Company Coordinates stock-summary
Company Details
Ul. Pojezierska 99 , LODZ None : 91-342
stock-summary
Tel: 48 42 6513152
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Urszula Grzegorzewska
Chairman of the Supervisory Board
Dr. Sebastian Kostecki
Member of the Supervisory Board
Ms. Anna Kowalska
Member of the Supervisory Board
Ms. Elzbieta Mikolajczyk
Member of the Supervisory Board
Mr. Andrzej Mozyszek
Member of the Supervisory Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
33 Million
(Quarterly Results - Mar 2025)
Net Profit:
2 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 53 Million (Micro Cap)

stock-summary
P/E

13.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

115.74%

stock-summary
Debt Equity

0.44

stock-summary
Return on Equity

10.23%

stock-summary
Price to Book

1.21